Literature DB >> 24951761

Pulmonary arterial hypertension: yesterday, today, tomorrow.

Evangelos D Michelakis1.   

Abstract

Entities:  

Keywords:  pulmonary arterial hypertension; pulmonary circulation; translational medical research

Mesh：

Year:  2014        PMID： 24951761     DOI： 10.1161/CIRCRESAHA.115.301132

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  10 in total

1.  Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Authors:  Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

2.  Nerve distribution of canine pulmonary arteries and potential clinical implications.

Authors:  Yun Zhang; Weijie Chen; Yanping Xu; Hang Liu; Yunlin Chen; Hanxuan Yang; Yuehui Yin
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  Celastrol attenuates the remodeling of pulmonary vascular and right ventricular in monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Huayang Li; Quan Liu; Yuan Yue; Shunjun Wang; Suiqing Huang; Lin Huang; Li Luo; Yitao Zhang; Zhongkai Wu
Journal:  Cardiovasc Diagn Ther       Date:  2022-02

4.  Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.

Authors:  Raymond L Benza; Mardi Gomberg-Maitland; Teresa Demarco; Adaani E Frost; Adam Torbicki; David Langleben; Tomas Pulido; Priscilla Correa-Jaque; Michael J Passineau; Howard W Wiener; Mayumi Tamari; Tomomitsu Hirota; Michiaki Kubo; Hemant K Tiwari
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

5.  Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.

Authors:  Arnica Behringer; Manuela Trappiel; Eva Maria Berghausen; Henrik Ten Freyhaus; Ernst Wellnhofer; Margarete Odenthal; Florian Blaschke; Fikret Er; Natig Gassanov; Stephan Rosenkranz; Stephan Baldus; Kai Kappert; Evren Caglayan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-07       Impact factor: 3.000

6.  Activation of Nrf2 Attenuates Pulmonary Vascular Remodeling via Inhibiting Endothelial-to-Mesenchymal Transition: an Insight from a Plant Polyphenol.

Authors:  Yucai Chen; Tianyi Yuan; Huifang Zhang; Yu Yan; Danshu Wang; Lianhua Fang; Yang Lu; Guanhua Du
Journal:  Int J Biol Sci       Date:  2017-09-03       Impact factor: 6.580

7.  Doxorubicin induced neuro- and cardiotoxicities in experimental rats: Protection against oxidative damage by Theobroma cacao Stem bark.

Authors:  A M Kosoko; O J Olurinde; O A Akinloye
Journal:  Biochem Biophys Rep       Date:  2017-02-07

8.  3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation.

Authors:  Jie Liu; Wang Wang; Lei Wang; Xian-Mei Qi; Yu-Hui Sha; Ting Yang
Journal:  Chin Med J (Engl)       Date:  2020-01-05       Impact factor: 2.628

9.  Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.

Authors:  Changhong Cai; Yijia Xiang; Yonghui Wu; Ning Zhu; Huan Zhao; Jian Xu; Wensheng Lin; Chunlai Zeng
Journal:  Mol Med Rep       Date:  2019-10-30       Impact factor: 2.952

10.  Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling.

Authors:  Anne L Theilmann; Lindsey G Hawke; L Rhiannon Hilton; Mara K M Whitford; Devon V Cole; Jodi L Mackeil; Kimberly J Dunham-Snary; Jeffrey Mewburn; Paula D James; Donald H Maurice; Stephen L Archer; Mark L Ormiston
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-01       Impact factor: 8.311
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.